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ABSTRACT 
Objective: Cervical cancer and other Human papillomavirus associated malignancies might be prevented by Human papillomavirus vaccines namely 
Gardasil®
Methods: We searched and analyzed reports of adverse events associated with HPV 2 and HPV4 vaccines from Vaccine Adverse Event Reporting 
System (VAERS). In United States, between the year2006-2013, total 24, 719 adverse events were reported after taking HPV2 and HPV4 vaccines. 
For HPV2 vaccine, we searched for reports from October 2009 to December 2013 and for HPV4 vaccine, we searched for reports from October 2006 
to December 2013.  
 (HPV4) - quadrivalent (Merck) and Cervarix™ (HPV2) - bivalent (GlaxoSmithKline) which are marketed internationally. The aim of this study 
is to analyze vaccines adverse events reporting system (VAERS) which is used for post-marketing passive surveillance (PMS) of licensed vaccines.  
Results: For HPV4 vaccine during 2006-2013, total 24, 460 adverse events and 84 deaths were reported while for HPV2 vaccine during 2009-2013, 
total 259 adverse events and 3 deaths were reported. Even after proper route of HPV vaccinesadministration i. e. intramuscular 13, 287 adverse 
events have been reported for HPV4 while 259 adverse events have been reported for HPV2 vaccine. The most frequently recorded adverse events 
due to HPV4 vaccine were found to be within the year 2006-2013 which included rash (2306 cases) followed by injection site erythrema (2245 
cases) and pyrexia (2142 cases). However, adverse events recorded for HPV2 vaccine were within the period 2009-2013 which included dizziness 
(37 cases) followed by headache (34 cases) and malaise (19 cases).  
Conclusion: In future ongoing HPV vaccines safety surveillance and further studies may shed light on some of the hypothesized associations.  
Keywords: Prophylactic Human papillomavirus vaccines, Virus-like particles, Post-marketing surveillance, Vaccine Adverse Event Reporting 
System, HPV2, HPV4.  
 
INTRODUCTION 
Human papillomaviruses are the primary etiological agents of 
cervical cancer. Thus, cervical cancer and other Human 
papillomavirus associated malignancies might be prevented by 
Human papillomavirus vaccines. Currently, two Human 
papillomavirus L1 Virus -Like Particle vaccines namely Gardasil® 
(HPV4) - quadrivalent (Merck) and Cervarix™ (HPV2) - bivalent 
(GlaxoSmithKline) are widely marketed internationally. Gardasil® is a 
quadrivalent HPV 16/18/6/11 L1 VLP vaccine (HPV4) developed by 
Merck and Co. Inc. , West Point, Pennsylvania, USA in collaboration 
with the Australian company CSL. Food and Drug Administration (US 
FDA) licensed this quadrivalent HPV vaccine in 2006 while INDIA 
licensed this vaccine in October 2008 for the use in females. 
Gardasil®issold in 109 countries.  [1, 2] Before FDA approved the use 
of Gardasil®, approximately 21, 000 girls and women were vaccinated 
with this HPV vaccine to evaluate the safety and its effectiveness. 
These studies showed that in women who have never been infected by 
HPV types 6, 11, 16 or 18, the vaccine was found to be highly effective 
in preventing precancerous lesions that often develop into cancer of 
the cervix, vagina and vulva and in preventing genital warts.  [3] From 
June 2006 through March 2013, approximately 56 million doses of 
HPV4 were distributed in United Nation [4]. 
Cervarix™ is the second human papillomavirus (HPV2) vaccine 
licensed for use in females in the United States which is 
manufactured by GlaxoSmithKline (GSK) Biologicals, Rixensart, 
Belgium in alliance with MedImmune. In September 2007, Cervarix™ 
was first approved by the European Union for use in girls and 
women in the age group of 10-35 years. 5On October 16, 2009, the 
FDA licensed bivalent human papillomavirus vaccine for use in 
females aged 10 through 25 years. Indian regulatory licensed this 
bivalent HPV vaccine in 2008 for use in females. Cervarix™issold in 
100 countries. 1Before FDA approved use of Cervarix™, its efficacy 
was assessed in the total of 19, 778 females used 15 through 25 
years of age to prevent histopathologically-confirmed CIN2/3 or AIS. 
6Both the HPV vaccines have been designed for prophylactic use 
only. These HPV vaccines need to administer intramuscularly. [1, 
5]From October 2009 through May 2013, a total of 611, 000 doses of 
HPV2 were distributed. 4The spontaneous safety reporting of any 
vaccines adverse events following immunization (AEFI) is the 
primary mechanism used for post-marketing passive surveillance 
(PMS) of licensed vaccines. Passive AEFI surveillance is common in 
many countries like INDIA. 7Post-licensure safety surveillance is 
important for a number of reasons. First, adverse events are reported 
after vaccinations but these are generally rare. Some adverse events 
are unlikely to be detected in prelicensure clinical trials because of 
their low frequency, the limited numbers of enrolled subjects, and 
other study limitations. Therefore, to overcome this post marketing 
monitoring of adverse events after vaccinations is essential. 8Second, 
for established vaccines PMSaims to monitor known adverse reactions 
and if the observed rate exceeds of adverse reactions the expected 
rate, further investigationis required. 9Vaccine Adverse Events 
Reporting System (VAERS) is a voluntary reporting system co 
administered by the Centers for Disease Control (CDC) and the Food 
and Drug Administration(FDA). It was established in 1990. VAERS 
accepts reports of adverse events after vaccination from vaccine 
manufacturers, healthcare providers, vaccine recipients, and others 
from United States of America (USA). VAERS generally cannot assess 
whether a vaccination caused an adverse event, but can identify 
possible vaccine safety problems for further investigation [10, 11].  
MATERIALS AND METHODS 
We searched and analyzed reports of adverse events of HPV2 and 
HPV4 vaccines which are submitted to theVaccine Adverse Event 
Reporting System (VAERS) by vaccine manufacturers, healthcare 
providers, vaccine recipients and others. For HPV2 vaccine, we 
searched for reports from October 2009 to December 2013. For 
HPV4 vaccine, we searched for reports from October 2006 to 
December 2013. Non-US reports were excluded. VAERS is a legally 
mandated, government-sponsored surveillance system. As a result, 
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there is no need of institutional review board approval and informed 
consent for this study. The numbers of adverse event reports in each 
of the states were calculated by year. For this study, we selected only 
HPV2 and HPV4 from VAERS database. The numbers of adverse 
event reports calculated in following age groups:1-10 yrs, 11-20 yrs, 
21-30 yrs, 31-40 yrs, 41-50 yrs, 51-60 yrs, 61-70 yrs, 71-80 yrs, 81-
90 yrs and 91-100 yrs. Incomplete reports were excluded from this 
analysis. Information we used from VAERS included demographics 
on the recipient (age, sex, etc,), type of vaccine, vaccination date, 
manufacturer, vaccine lot number, doses previously received, date of 
onset of symptoms and description of the event and deaths.  
RESULTS 
In U. S. states, within 2006-2013 period, total 24, 719 adverse events 
reported after taking both (HPV2 and HPV4) vaccines. Out of all U. S. 
states, 1245 adverse events were reported in CA. Maximum adverse 
events were recorded in the year 2008. The 12, 500 reported 
adverse events do not know have the source of information from 
which states events reported for both vaccines. During 2006-2013, 
for HPV4 vaccine total 24, 460 adverse events and 84 deaths 
reported. In CA state, within 2006-2013 periods for HPV4 
vaccine1244 adverse events recorded. The 6100 adverse events 
recorded in the year 2008. There are 12, 427 adverse events that do 
not have a record of the State from which they have been reported. 
For HPV2 vaccine during 2009-2013 periods, total 259 adverse 
events and 3 deaths have been reported. In FR state, within 2009-
2013 periods 146 adverse events recorded for HPV2 vaccine. 
Maximum number of adverse events was recorded in the year 2009 
of these total 73 adverse events did not have the source of 
information from which states such events have been reported.  
 
Table 1: It shows Vaccine Adverse Event Reporting System (VAERS) reported rates for HPV (HP2 and HPV4) vaccines in states United 
States, 2006-2013 
States Numbers Total 
2006 2007 2008 2009 2010 2011 2012 2013 
AK 0 4 15 10 4 4 0 3 40 
AL 0 23 25 19 15 13 0 7 102 
AR 0 10 26 18 13 17 0 2 86 
AZ 0 64 65 57 32 50 0 20 288 
CA 1 272 334 239 157 168 0 74 1245 
CO 0 60 70 59 24 28 0 8 249 
CT 0 34 48 28 16 30 0 5 161 
DC 0 9 9 16 5 8 0 4 51 
DE 0 10 9 7 7 6 0 0 39 
FL 0 105 154 108 49 89 0 58 563 
FR 0 0 0 146 0 0 0 0 146 
GA 0 88 96 77 36 46 0 11 354 
GU 0 3 1 1 0 1 0 1 7 
HI 0 11 9 13 8 11 0 3 55 
IA 0 41 40 35 11 20 0 3 150 
ID 0 15 22 18 5 20 0 7 87 
IL 0 70 100 91 46 61 0 36 404 
IN 0 52 59 63 30 25 0 12 241 
KS 0 14 20 94 17 12 0 2 159 
KY 0 36 37 41 16 33 0 7 170 
LA 0 24 26 24 11 22 0 5 112 
MA 0 79 97 74 34 51 0 23 358 
MD 0 47 59 45 36 31 0 12 230 
ME 0 23 26 14 8 19 0 5 95 
MI 0 102 128 99 48 50 0 25 452 
MN 0 71 70 63 28 40 0 11 283 
MO 1 64 68 65 30 39 0 5 272 
MS 0 14 15 13 9 12 0 4 67 
MT 0 12 21 26 5 8 0 2 74 
NC 0 78 125 108 45 59 0 21 436 
States Numbers Total 
2006 2007 2008 2009 2010 2011 2012 2013 
ND 0 16 13 6 2 8 0 4 49 
NE 0 23 31 20 7 8 0 2 91 
NH 0 14 20 18 13 10 0 11 86 
NJ 0 56 83 60 36 37 0 22 294 
NM 0 34 26 20 8 17 0 6 111 
NV 0 22 15 23 10 11 0 5 86 
NY 0 160 139 126 78 75 0 34 612 
OH 0 110 146 78 51 66 0 22 473 
OK 0 32 28 27 14 20 0 9 130 
OR 0 31 59 46 14 24 0 15 189 
PA 0 155 172 116 72 78 0 27 620 
PR 0 6 7 8 7 2 0 3 33 
RI 0 14 10 15 8 4 0 1 52 
SC 0 27 33 27 14 15 0 13 129 
SD 0 7 14 7 4 5 0 6 43 
TN 0 44 60 55 24 25 0 12 220 
TX 0 180 197 147 64 107 0 38 733 
UT 0 16 25 26 5 22 0 7 101 
VA 0 85 83 86 35 42 0 25 356 
VI 0 4 3 2 1 1 0 0 11 
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VT 0 5 15 6 6 8 0 1 41 
WA 0 89 81 80 34 57 0 23 364 
WI 0 61 71 72 28 48 0 14 294 
WV 0 22 23 24 5 15 0 6 95 
WY 0 12 8 1 3 6 0 0 30 
Unknown 426 3060 2964 637 1462 634 2530 787 12500 
Total 428 5720 6100 3404 2750 2318 2530 1469 24719 
 
In U. S. states, within 2006-2013 period, on the basis of gender total 
24, 742 adverse events reported after taking HPV vaccines. Total 
4352 adverse events were reported in male and 8682 adverse 
events were reported in female. For HPV4 vaccine during 2006-
2013 period, total 24, 483 adverse events were reported. While 
4334 adverse events were reported in male and 8509 adverse 
events reported in female. In the year 2008, 6100 adverse events 
have been recorded. Total 11, 640 adverse events reported for 
which information regarding gender was unknown. During 2009-
2013 periods 259 adverse events were reported. Of these 18 
adverse events reported in male and 173 adverse events were 
reported in female. In the year 2009, 146 adverse events recorded. 
Of which 68 adverse events had been reported whose information 
regarding gender was unknown. 
  
Table 2: It shows vaccine Adverse Event reporting System (VAERS) reported rates on the basis of sex for HPV (HP2 and HPV4) vaccines in 
United States, 2006-2013 
Sex Numbers Total 
2006 2007 2008 2009 2010 2011 2012 2013  
M 0 923 1105 915 524 612 0 273 4352 
F 2 1935 2242 1966 883 1164 0 490 8682 
Unknown 426 2862 2753 523 1366 542 2530 706 11708 
Total 428 5720 6100 3404 2773 2318 2530 1469 24742 
 
In U. S. Nation, for HPV4 vaccine during 2006-2013 periods, on the 
basis of month total 26, 439 adverse events were reported. In the 
month October, 2141 adverse events were recorded. Total 9739 
adverse events were reported for which information regarding month 
was unknown. For HPV2 vaccine during 2009-2013 periods, on the 
basis of month total 249 adverse events were reported. In the month 
November, 76 adverse events recorded. Total 37 adverse events 
reported whose source of information regarding month was unknown. 
 
Table 3: It shows vaccine adverse event reporting system (VAERS) reported rates on the basis of month for HPV (HP2 and HPV4) vaccines 
in United States, 2006-2013 
Months Numbers Total 
2006 2007 2008 2009 2010 2011 2012 2013 
January 0 153 169 235 76 108 80 129 950 
February 0 108 232 213 65 86 83 93 880 
March 0 269 302 400 89 67 93 118 1338 
April 0 140 203 214 134 105 94 108 998 
May 0 298 367 561 120 109 77 134 1666 
June 0 257 316 287 75 107 91 77 1210 
July 0 393 496 391 108 177 102 33 1700 
August 0 142 207 143 73 121 153 29 868 
September 0 191 261 861 182 173 227 11 1906 
October 0 417 349 726 184 173 296 37 2182 
November 2 402 383 595 132 372 149 43 2078 
December 0 176 168 338 158 171 102 23 1136 
Unknown 426 2766 2617 457 1367 564 940 639 9776 
Total 428 5712 6070 5421 2763 2333 2487 1474 26688 
 
Table 4: It shows vaccine Adverse Event reporting System (VAERS) reported rates on the basis of age group for HPV (HP2 and HPV4) 
vaccines in United States, 2006-2013 
Year Numbers Total 
Age groups 
0 to 10 11 to 20 21 to 30 31 to 40 41 to 50 51 to 60 61 to 70 71 to 80 81 to 90 91 to 100 Unknown 
2006 1 0 0 0 0 1 0 0 0 0 426 428 
2007 961 586 265 157 158 183 201 141 37 5 3026 5720 
2008 1084 691 317 201 202 223 289 154 51 4 2884 6100 
2009 865 624 301 236 211 203 217 86 30 2 614 3389 
2010 429 184 152 111 120 121 149 80 35 5 1375 2761 
2011 466 241 174 126 150 189 241 114 40 7 555 2303 
2012 0 0 0 0 0 0 0 0 0 0 2493 2493 
2013 223 113 49 60 50 86 117 30 10 0 724 1462 
Total 4029 2439 1258 891 891 1006 1214 605 203 23 12097 24656 
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In U. S. states, within 2006-2013 period, maximum 4029 adverse 
event reported in the age group (0 to 10 years) after taking HPV 
vaccines. In US states, for HPV4 vaccine during 2006-2013 periods, 
on the basis of age group total 24, 483 adverse events were 
reported. The 4015 adverse events was recorded for the age group 0 
to 10 yr. Total 12, 097 adverse events reported whose source of 
information regarding age group was unknown. For HPV2 vaccine 
during 2009-2013 periods, on the basis of age group total 173 
adverse events were reported. The 122 adverse events recorded for 
the age group 11 to 20 yr. VAERS data must be interpreted 
cautiously. VAERS is a passive surveillance system with limitations 
that include both underreporting and biased reporting that can 
affect the outcome and analysis [8]. 
In U. S. states, within 2006-2013 period, 5218 adverse events reported 
after taking 1st dose of HPV vaccines. For HPV4 vaccine during 2006-
2013 periods, based onthe vaccine doses total 24, 497 adverse events 
were reported. For HPV4 vaccine, after administration of 1st dose 
maximum 5168 of adverse events reported from 2006- 2013. For HPV2 
vaccine during 2009-2013 periods, on the basis of vaccine dose total 259 
adverse events were reported. Total 110 adverse events reported whose 
source of information regarding vaccine dose was unknown. 
  
Table 5: It shows vaccine adverse event reporting system (VAERS) reported rates on the basis of dose administration for HPV (HP2 and 
HPV4) vaccines in United States, 2006-2013 
Vaccine dose Numbers Total 
2006 2007 2008 2009 2010 2011 2012 2013 
0 205 2855 2799 1484 1275 1188 996 444 11246 
1 27 1052 1326 790 572 452 614 385 5218 
2 2 322 856 594 437 365 430 216 3222 
3 0 6 39 32 27 11 21 10 146 
4 0 1 3 1 1 0 0 0 6 
5 0 1 5 2 0 1 0 0 9 
6 0 0 0 0 1 0 0 0 1 
7 0 0 2 0 0 0 0 0 2 
8 0 0 0 0 0 1 0 0 1 
20 0 0 1 0 0 0 0 0 1 
Unknown 192 1483 1069 521 437 339 469 414 4924 
Total 426 5720 6100 3424 2750 2357 2530 1469 24776 
 
Within 2006-2013 period, intramuscular route of HPV vaccine 
administration reported maximum adverse events. For HPV4 vaccine 
during 2006-2013 periods in US, on the basis of HPV vaccination route 
total 24, 522 adverse events were reported. For HPV4 vaccine, adverse 
events reported after administration of HPV4 vaccine via proper route i. 
e. intramuscular is 13287. However, in reported 10665 adverse events 
the route of HPV4 vaccination is unknown. For HPV2 vaccine during 
2009-2013 periods in US, on the basis of HPV vaccination route total 259 
adverse events were reported. For HPV2 vaccine, adverse events 
reported after administration of HPV2 vaccine via proper route i. e. 
intramuscular is 157. However, in reported 89 adverse events the route 
of HPV4 vaccination is unknown.  
 
Table 6: It shows vaccine Adverse Event reporting System (VAERS) reported rates on the basis of route of HPV vaccine administration for 
HPV (HP2 and HPV4) vaccines in United States, 2006-2013 
Vaccine route Numbers Total 
2006 2007 2008 2009 2010 2011 2012 2013 
ID 0 9 10 11 2 0 1 1 34 
IJ 0 30 16 37 111 91 0 0 285 
IM 238 3062 3152 1860 1405 1342 1494 891 13444 
IN 0 6 4 0 0 0 0 0 10 
PO 1 2 3 1 0 0 0 0 7 
SC 1 42 30 16 5 15 12 9 130 
SYR 0 0 0 0 0 9 65 43 117 
Unknown 188 2569 2885 1479 1250 900 958 525 10754 
Total 428 5720 6100 3404 2773 2357 2530 1469 24781 
 
In 2006-2013 period, 24, 775 adverse events were recorded by 
different sources in VAERS system after HPV vaccines 
administration. Out of reported total 24, 775 adverse events within 
2006-2013 period, maximum adverse events reported after the 
administration HPV4 vaccine by unknown source are 11469. Others 
reported source are PVT- 5101, OTH- 4856 and PUB-2355. Out of 
reported total 259 adverse events within 2009-2013 period, 
maximum adverse events reported after the administration HPV2 
vaccine by other source 184 followed by unknown- 40, PVT- 21 and 
PUB-11.
.  
Table 7: It shows vaccine adverse event reporting system (VAERS) reported rates on the basis of route of HPV vaccine administration for 
HPV (HP2 and HPV4) vaccines in United States, 2006-2013 
Vaccine administered by Numbers Totals 
2006 2007 2008 2009 2010 2011 2012 2013 
MIL 0 118 172 199 75 72 74 34 744 
PUB 1 433 472 499 282 322 240 117 2366 
PVT 0 1199 1248 923 447 635 434 236 5122 
OTH 0 963 1080 836 509 600 683 363 5034 
Unknown 427 3007 3128 941 1460 728 1099 719 11509 
Totals 428 5720 6100 3398 2773 2357 2530 1469 24775 
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In 2006-2013 period, the most frequently recorded adverse event 
recorded adverse events due to HPV vaccination were rash- 2319 
followed by injection site erythema- 2260 and pyrexia-2155. The most 
frequently recorded adverse event for HPV4 vaccine within 2006-2013 
period was rash- 2306 followed by injection site erythema- 2245 and 
pyrexia- 2142. The most common local adverse reactions reported due 
to HPV4 were injection site pain-1459, injection site swelling- 1638, 
injection site erythema- 2260, injection site pruritus- 405 and injection 
site bruising- 34. However, the most frequently recorded adverse event 
for HPV2 vaccine within 2009-2013 period is dizziness- 37 followed by 
headache- 34 and malaise- 19. The most common local adverse reactions 
reported due to HPV2 were injection site pain- 12 and injection site 
swelling- 10. The most common general adverse events were fatigue- 15, 
headache- 34, myalgia- 4 and arthralgia- 9. Most reports cannot prove 
whether vaccination caused the subsequent symptoms. Not all adverse 
events that occur after vaccination are reported and many reports 
describe events that may have been caused by confounding factors, 
including medications and diseases [11]. 
CONCLUSION 
Vaccination with HPV2 and HPV4 has the great potential to decrease 
the global morbidity and mortality of HPV associated diseases, 
including cervical cancer. First time due to this study we are able to 
compare the HPV2 and HPV4 vaccine risk profile by using VAERS 
data. VAERS has been used as an important surveillance tool and 
demonstrated to be very helpful when assessing vaccine safety. 
Among all reports, frequencies of solicited adverse events after 
vaccination with HPV2 and HPV4 vaccine were higher than those 
reported in prior studies and those currently listed in the package 
insert. Therefore, the safety profile of both HPV vaccines needs to be 
considered in the context of the benefits of vaccination which 
includes the disease epidemiology and the vaccine effectiveness. In 
future ongoing HPV vaccines safety surveillance and further studies 
may shed light on some of the hypothesized associations.  
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